Emergent BioSolutions’ (EBS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a research note published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $15.00 target price on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on the stock. StockNews.com raised shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Benchmark boosted their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th.

Emergent BioSolutions Price Performance

Shares of NYSE EBS opened at $11.45 on Tuesday. The firm has a market cap of $620.09 million, a P/E ratio of -2.79 and a beta of 1.60. The business’s 50 day moving average is $9.27 and its 200-day moving average is $9.27. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. Emergent BioSolutions has a 1-year low of $1.42 and a 1-year high of $15.10.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.37 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.88. The firm had revenue of $293.80 million for the quarter, compared to analysts’ expectations of $328.72 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same quarter last year, the business earned ($1.44) EPS. Equities research analysts predict that Emergent BioSolutions will post -0.63 earnings per share for the current year.

Hedge Funds Weigh In On Emergent BioSolutions

Several hedge funds have recently bought and sold shares of the company. Stifel Financial Corp acquired a new stake in shares of Emergent BioSolutions during the 3rd quarter worth approximately $96,000. FORA Capital LLC bought a new stake in Emergent BioSolutions during the third quarter worth $103,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Emergent BioSolutions in the 2nd quarter valued at $93,000. Morse Asset Management Inc bought a new position in shares of Emergent BioSolutions in the 2nd quarter valued at $97,000. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of Emergent BioSolutions during the 3rd quarter worth $141,000. 78.40% of the stock is owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.